Daré Bioscience (DARE) to Release Earnings on Monday

Daré Bioscience (NASDAQ:DARE) is scheduled to release its earnings data after the market closes on Monday, August 12th. Analysts expect Daré Bioscience to post earnings of ($0.57) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.12). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.52 million. During the same period last year, the firm earned ($1.08) earnings per share. On average, analysts expect Daré Bioscience to post $-3 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Daré Bioscience Stock Up 0.9 %

Shares of DARE traded up $0.03 during trading hours on Tuesday, reaching $3.29. 12,743 shares of the company traded hands, compared to its average volume of 47,950. Daré Bioscience has a 12 month low of $3.05 and a 12 month high of $9.47. The company has a market capitalization of $27.70 million, a price-to-earnings ratio of -0.83 and a beta of 1.37. The company’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $4.68.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DARE. HC Wainwright reiterated a “buy” rating and issued a $72.00 target price on shares of Daré Bioscience in a research note on Wednesday, May 15th. Brookline Capital Management upgraded Daré Bioscience from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Wednesday, May 15th.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.